Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Autolus Therapeutics Ltd

AUTL
Current price
4.02 USD +0.06 USD (+1.52%)
Last closed 3.92 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 1 042 861 120 USD
Yield for 12 month +25.23 %
1Y
3Y
5Y
10Y
15Y
AUTL
21.11.2021 - 28.11.2021

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.69 USD

P/E ratio

Dividend Yield

Current Year

+1 698 000 USD

Last Year

+6 194 000 USD

Current Quarter

+10 091 000 USD

Last Quarter

+1 775 000 USD

Current Year

-4 867 000 USD

Last Year

-131 026 000 USD

Current Quarter

+8 285 000 USD

Last Quarter

Key Figures AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -172 597 744 USD
Operating Margin TTM -384.08 %
PE Ratio
Return On Assets TTM -16.43 %
PEG Ratio
Return On Equity TTM -52.13 %
Wall Street Target Price 10.69 USD
Revenue TTM 10 497 000 USD
Book Value 2.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 681 %
Dividend Yield
Gross Profit TTM -130 860 000 USD
Earnings per share -1.21 USD
Diluted Eps TTM -1.21 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AUTL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AUTL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 676.2963
Price Sales TTM 786.1887
Enterprise Value EBITDA -7.3251
Price Book MRQ 11.9754

Financials AUTL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AUTL

For 52 weeks

2.01 USD 7.45 USD
50 Day MA 4.84 USD
Shares Short Prior Month 3 522 989
200 Day MA 4.53 USD
Short Ratio 2.11
Shares Short 3 252 017
Short Percent 1.79 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.16 USD Microsoft Corporation +3.16 (+0.74%)
Detailed analytics

ETF funds


S

SX7EEX

14.70 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.1 (+0.64%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics